title: [Pomalidomide for multiple myeloma].
abstract: Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This review focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: G
authors.initials: G
authors.lastname: Fouquet
authors.affiliation: Hématologie, hôpital Côte-de-Nacre, CHU, 1400 Caen, France.
authors.forename: M
authors.initials: M
authors.lastname: Macro
authors.affiliation: Médecine interne, hôpital Sud, CHRU, 35000 Rennes, France.
authors.forename: O
authors.initials: O
authors.lastname: Decaux
authors.affiliation: Hématologie, hôpital Hautepierre, CHU, 67000 Strasbourg, France.
authors.forename: C
authors.initials: C
authors.lastname: Fohrer
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: S
authors.initials: S
authors.lastname: Guidez
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: H
authors.initials: H
authors.lastname: Demarquette
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Le Grand
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Prodhomme
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Renaud
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Bories
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Herbaux
authors.affiliation: Service d'hématologie, hôpital Lyon-Sud, CHU, 69000 Lyon - Pierre-Bénite, France.
authors.forename: L
authors.initials: L
authors.lastname: Karlin
authors.affiliation: Hématologie clinique, hôpital Purpan, CHU, 31000 Toulouse, France.
authors.forename: M
authors.initials: M
authors.lastname: Roussel
authors.affiliation: Onco-hématologie, hôpital Bretonneau, CHRU, 37000 Tours, France.
authors.forename: L
authors.initials: L
authors.lastname: Benboubker
authors.affiliation: Hématologie, hôpitaux de Brabois, CHU, 54000 Vandœuvre-lès-Nancy, France.
authors.forename: C
authors.initials: C
authors.lastname: Hulin
authors.affiliation: Hématologie-immunologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Arnulf
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France. Electronic address: xavier.leleu@chru-lille.fr.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D008968:Molecular Conformation; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology; D013329:Structure-Activity Relationship; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; C467566:pomalidomide
keywords: IMiD; Immunomodulation; Multiple myeloma; Myélome multiple; Pomalidomide